Celcuity's REVTORPYK Receives Recommendation From National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology As Preferred Category 1 Second-Line Therapy
Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced that REVTORPYK™ (gedatolisib) in combination with
Celcuity's cancer medicine got a big thumbs-up from doctors' guidelines, saying it's a top choice for certain patients. When smart doctors recommend a treatment as a first choice, it usually helps the company sell more medicine.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.